Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01831609

Enrollment

1000

Registered

2013-04-15

Start date

2011-08-31

Completion date

2024-12-31

Last updated

2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Keywords

Gastrointestinal, Genitourinary, Rare Cancer

Brief summary

To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer 2. Written informed consent 3. body fluid derived from cancer, available for drainage and collection

Exclusion criteria

* patients who do not give informed consent form for research use of biomaterials/biospecimens

Design outcomes

Primary

Measure	Time frame	Description
Biomarker analyses to predict treatment response in metastatic cancer	3 year	Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.

Countries

South Korea

Contacts

Primary ContactJeeyun Lee, MD

jyun.lee@samsung.com822-3410-3459

Outcome results